Investor Centre
Our broad clinical and preclinical pipeline in oncology and behavioural brain disorders focuses on indications including glioblastoma, neurodevelopmental disorders, addiction, anxiety, fatigue and narcolepsy.
TheraCryf plc Investor Presentation

09 - July - 2025
TheraCryf shares the corporate presentation following the AGM held on the 9th July 2025.
Major Shareholders
Current Shareholder | Number of shares | Percentage holding |
---|---|---|
Northern Standard Limited | 422,727,272 | 19.67% |
First Equity Limited | 179,000,000 | 8.33% |
T and I Limited | 160,000,000 | 7.45% |
Spreadex Limited | 93,050,001 | 4.33% |
Oberon Investments Limited | 80,475,000 | 3.74% |
A Leach | 80,000,000 | 3.72% |
S Gibeon | 71,400,000 | 3.32% |
J. R. Kight | 56,100,000 | 2.61% |
Rathbones Investment Management Ltd | 24,835,704 | 1.16% |
Octopus Investments | 21,875,000 | 1.02% |
Vulpes Investment Management Pte Ltd | 20,554,191 | 0.96% |
Seneca Partners Limited | 16,301,456 | 0.76% |
The number of ordinary shares in issue is 2,148,963,739. Directors hold 13,184,793 and 2,135,778,946 are in public hands. The Company does not hold any shares in the Treasury.